Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W McIntyre

Showing results (461-470 of 505) with videos related to

Pageof 51
Sort By:
ACS Medicinal Chemistry Letters|September 18, 2020
Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P<sub>1</sub>) Modulators: Optimization of the PK, PD, and Safety ProfilesZili Xiao, Michael G Yang, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|June 26, 2007
Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2- fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419)Scott H Watterson, Ping Chen, Yufen Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitorJohn Hynes, Hong Wu, Sidney Pitt, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 28, 2015
Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of AutoimmunityPaul R Mangan, Linhui Julie Su, Victoria Jenny, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 23, 2016
Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing ActivityShailesh Dudhgaonkar, Sourabh Ranade, Jignesh Nagar, et al.
Journal of Medicinal Chemistry|January 25, 2021
Bicyclic Ligand-Biased Agonists of S1P<sub>1</sub>: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety ProfilesJohn L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|December 28, 2020
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2Chunjian Liu, James Lin, Charles Langevine, et al.
Acta Neuropathologica Communications|March 12, 2025
Granular cytoplasmic inclusions in astrocytes and microglial activation in the fetal brain of pigtail macaques in response to maternal viral infectionRaj P Kapur, Andrew E Vo, Amanda Li, et al.
Journal of Medicinal Chemistry|August 20, 2004
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activityPing Chen, Arthur M Doweyko, Derek Norris, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid ArthritisSteven H Spergel, Michael E Mertzman, James Kempson, et al.
Pageof 51

Showing results (461-470 of 505) with videos related to

Sort By:
Pageof 51
ACS Medicinal Chemistry Letters|September 18, 2020
Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P<sub>1</sub>) Modulators: Optimization of the PK, PD, and Safety ProfilesZili Xiao, Michael G Yang, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|June 26, 2007
Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2- fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419)Scott H Watterson, Ping Chen, Yufen Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitorJohn Hynes, Hong Wu, Sidney Pitt, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 28, 2015
Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of AutoimmunityPaul R Mangan, Linhui Julie Su, Victoria Jenny, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 23, 2016
Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing ActivityShailesh Dudhgaonkar, Sourabh Ranade, Jignesh Nagar, et al.
Journal of Medicinal Chemistry|January 25, 2021
Bicyclic Ligand-Biased Agonists of S1P<sub>1</sub>: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety ProfilesJohn L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|December 28, 2020
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2Chunjian Liu, James Lin, Charles Langevine, et al.
Acta Neuropathologica Communications|March 12, 2025
Granular cytoplasmic inclusions in astrocytes and microglial activation in the fetal brain of pigtail macaques in response to maternal viral infectionRaj P Kapur, Andrew E Vo, Amanda Li, et al.
Journal of Medicinal Chemistry|August 20, 2004
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activityPing Chen, Arthur M Doweyko, Derek Norris, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid ArthritisSteven H Spergel, Michael E Mertzman, James Kempson, et al.
Pageof 51